{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:51:56Z","timestamp":1784152316032,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jad.2020.11.006","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T17:05:17Z","timestamp":1604595917000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"PA","title":["Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression"],"prefix":"10.1016","volume":"280","author":[{"given":"Filippo","family":"Cant\u00f9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ciappolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-2699","authenticated-orcid":false,"given":"Paolo","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-1980","authenticated-orcid":false,"given":"Giuseppe","family":"Delvecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2020.11.006_bib0001","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0006-3223(03)00087-8","article-title":"Acceleration and augmentation strategies for treating bipolar depression","volume":"53","author":"Altshuler","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2020.11.006_bib0002","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study","author":"Bauer","year":"2009","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.jad.2020.11.006_bib0003","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","author":"Berman","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.jad.2020.11.006_bib0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jad.2020.11.006_bib0005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14737175.2019.1653759","article-title":"Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder","volume":"19","author":"Cha","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jad.2020.11.006_bib0006","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/da.20130","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression","volume":"23","author":"Corya","year":"2006","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2020.11.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1920-7","article-title":"Humanistic outcomes in treatment resistant depression: A secondary analysis of the STAR\u2217D study","author":"Dibernardo","year":"2018","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.jad.2020.11.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2005.08.012","article-title":"To combine or not to combine? A literature review of antidepressant combination therapy","author":"Dodd","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2020.11.006_bib0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YIC.0b013e32836220df","article-title":"The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression","volume":"28","author":"Dording","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2020.11.006_bib0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079906X162809","article-title":"Quetiapine augmentation of treatment-resistant depression: A comparison with lithium","volume":"23","author":"Dor\u00e9e","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2020.11.006_bib0011","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study","volume":"13","author":"El-Khalili","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2020.11.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19686","article-title":"Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic","author":"Ettman","year":"2020","journal-title":"JAMA Netw. open"},{"key":"10.1016\/j.jad.2020.11.006_bib0013","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2020.11.006_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000332050","article-title":"A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)","volume":"81","author":"Fava","year":"2012","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2020.11.006_bib0015","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1080\/14656566.2019.1654457","article-title":"Brexpiprazole for treatment-resistant major depressive disorder","volume":"20","author":"Fornaro","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jad.2020.11.006_bib0016","article-title":"Depression Is the Leading Cause of Disability Around the World","author":"Friedrich","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.jad.2020.11.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: A PET study","author":"Gefvert","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2020.11.006_bib0018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/YIC.0000000000000196","article-title":"Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression","volume":"33","author":"Gobbi","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2020.11.006_bib0019","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v67n0304","article-title":"Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: A secondary analysis from a randomized, double-blind, placebo-controlled study","author":"Hirschfeld","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2020.11.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","author":"Janssen","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2020.11.006_bib0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/WNF.0b013e3182a31f3d","article-title":"Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: A 6-Week prospective, open-label, multicenter study","volume":"36","author":"Jon","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2020.11.006_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study","author":"Kapur","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.jad.2020.11.006_bib0023","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2020.11.006_bib0024","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2020.11.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-publhealth-031912-114409","article-title":"The Epidemiology of Depression Across Cultures","author":"Kessler","year":"2013","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.jad.2020.11.006_bib0026","article-title":"Second-generation antipsychotics for major depressive disorder and dysthymia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2020.11.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.jad.2020.11.006_bib0028","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1176\/appi.neuropsych.12070171","article-title":"The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: A clinical study","volume":"25","author":"Li","year":"2013","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2020.11.006_bib0029","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: A randomized trial","author":"Mahmoud","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jad.2020.11.006_bib0030","first-page":"302","article-title":"Treatment-resistant depression: Resistant to definition? Acta Psychiatr","volume":"112","author":"Malhi","year":"2005","journal-title":"Scand"},{"key":"10.1016\/j.jad.2020.11.006_bib0031","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder","volume":"28","author":"Marcus","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2020.11.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/da.20275","article-title":"Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study","author":"McIntyre","year":"2007","journal-title":"Depress. Anxiety."},{"key":"10.1016\/j.jad.2020.11.006_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2020.11.006_bib0034","series-title":"Treating Resistant Depression","first-page":"131","article-title":"The use of antipsychotic drugs in the treatment of depression","author":"Nelson","year":"1987"},{"key":"10.1016\/j.jad.2020.11.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials","author":"Nelson","year":"2009","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.jad.2020.11.006_bib0036","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v68n0602","article-title":"Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis","author":"Papakostas","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2020.11.006_bib0037","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291700033146","article-title":"Residual Symptoms After Partial Remission: An Important Outcome in Depression","author":"Paykel","year":"1995","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2020.11.006_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2019.08.009","article-title":"Can Machine Learning help us in dealing with treatment resistant depression? A review","author":"Pigoni","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2020.11.006_bib0039","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301113","article-title":"Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation","volume":"31","author":"Rapaport","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2020.11.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","author":"Richelson","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.jad.2020.11.006_bib0041","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jad.2020.11.006_bib0042","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2020.11.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/070674371005500303","article-title":"The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: A review","author":"Sinyor","year":"2010","journal-title":"Can. J. Psychiatry."},{"key":"10.1016\/j.jad.2020.11.006_bib0044","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0924-977X(98)00004-2","article-title":"Treatment resistant depression: Methodological overview and operational criteria","volume":"9","author":"Souery","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2020.11.006_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.jad.2020.11.006_bib0046","unstructured":"Stahl, S.M., 2008. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications, 4th ed., Stahl's essential psychopharmacology: Neuroscientific basis and practical applications, 3rd ed."},{"key":"10.1016\/j.jad.2020.11.006_bib0047","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.2018.233","article-title":"Augmentation therapies for treatment-resistant depression: Systematic review and meta-analysis","volume":"214","author":"Strawbridge","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2020.11.006_bib0048","article-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2010","journal-title":"Psychiatria Danubina"},{"key":"10.1016\/j.jad.2020.11.006_bib0049","article-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics","author":"Thompson Coon","year":"2010","journal-title":"Focus Altern. Complement. Ther"},{"key":"10.1016\/j.jad.2020.11.006_bib0050","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2020.11.006_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010","author":"Whiteford","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.jad.2020.11.006_bib0052","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: Systematic review and network meta-analysis","author":"Zhou","year":"2015","journal-title":"J. Clin. Psychiatry."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032720329347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032720329347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:45:20Z","timestamp":1759023920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032720329347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":52,"alternative-id":["S0165032720329347"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2020.11.006","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2020.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}